Compile Data Set for Download or QSAR
Report error Found 124 Enz. Inhib. hit(s) with all data for entry = 7646
TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208981(US9233167, Morphine | (4R,4aR,7S,7aR,12bS)-3-methy...)
Affinity DataKi:  8.44nM ΔG°:  -46.1kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataKi:  14.3nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208982(US9233167, a-6-mPEG1-O-Morphine)
Affinity DataKi:  15.7nM ΔG°:  -44.5kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209007(US9233167, 6-O-mPEG4-Nalbuphine)
Affinity DataKi:  17.5nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208983(US9233167, a-6-mPEG2-O-Morphine)
Affinity DataKi:  22.0nM ΔG°:  -43.7kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208985(US9233167, a-6-mPEG4-O-Morphine)
Affinity DataKi:  23.1nM ΔG°:  -43.6kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataEC50:  25.1nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208977(US9233167, 6-O-mPEG3-Nalbuphine)
Affinity DataEC50:  26.8nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208977(US9233167, 6-O-mPEG3-Nalbuphine)
Affinity DataKi:  27.4nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208981(US9233167, Morphine | (4R,4aR,7S,7aR,12bS)-3-methy...)
Affinity DataEC50:  28.5nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataKi:  29.9nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209008(US9233167, 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  35.1nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209008(US9233167, 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  35.6nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208986(US9233167, a-6-mPEG5-O-Morphine)
Affinity DataKi:  39.4nM ΔG°:  -42.3kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  44.3nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208984(US9233167, a-6-mPEG3-O-Morphine)
Affinity DataKi:  50.7nM ΔG°:  -41.6kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208988(US9233167, a-6-mPEG7-O-Morphine)
Affinity DataKi:  56.9nM ΔG°:  -41.4kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208987(US9233167, a-6-mPEG6-O-Morphine)
Affinity DataKi:  73.0nM ΔG°:  -40.7kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209010(US9233167, 6-O-mPEG7-Nalbuphine)
Affinity DataKi:  77.9nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209009(US9233167, 6-O-mPEG8-Nalbuphine)
Affinity DataKi:  79.5nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208982(US9233167, a-6-mPEG1-O-Morphine)
Affinity DataEC50:  85nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208983(US9233167, a-6-mPEG2-O-Morphine)
Affinity DataEC50:  93.3nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208989(US9233167, a-6-mPEG9-O-Morphine)
Affinity DataKi:  111nM ΔG°:  -39.7kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208981(US9233167, Morphine | (4R,4aR,7S,7aR,12bS)-3-methy...)
Affinity DataKi:  118nM ΔG°:  -39.5kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208979(US9233167, 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  122nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208985(US9233167, a-6-mPEG4-O-Morphine)
Affinity DataEC50:  128nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  130nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50370595(US9233167, Oxycodone | Oxycontin | OXYCODONE | US1...)
Affinity DataKi:  133nM ΔG°:  -39.2kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209008(US9233167, 6-O-mPEG5-Nalbuphine)
Affinity DataKi:  148nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209007(US9233167, 6-O-mPEG4-Nalbuphine)
Affinity DataKi:  149nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208986(US9233167, a-6-mPEG5-O-Morphine)
Affinity DataEC50:  157nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208979(US9233167, 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  158nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208977(US9233167, 6-O-mPEG3-Nalbuphine)
Affinity DataKi:  163nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataEC50:  164nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209009(US9233167, 6-O-mPEG8-Nalbuphine)
Affinity DataKi:  168nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208979(US9233167, 6-O-mPEG9-Nalbuphine)
Affinity DataKi:  186nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208977(US9233167, 6-O-mPEG3-Nalbuphine)
Affinity DataKi:  218nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataKi:  247nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208984(US9233167, a-6-mPEG3-O-Morphine)
Affinity DataEC50:  270nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209009(US9233167, 6-O-mPEG8-Nalbuphine)
Affinity DataKi:  282nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208978(US9233167, 6-O-mPEG6-Nalbuphine)
Affinity DataIC50: 284nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209010(US9233167, 6-O-mPEG7-Nalbuphine)
Affinity DataKi:  314nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetDelta-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50105085(US9233167, Nalbuphine | 17-cyclobutylmethyl-4,5alp...)
Affinity DataKi:  319nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM209010(US9233167, 6-O-mPEG7-Nalbuphine)
Affinity DataKi:  346nMAssay Description:Specific binding is determined by subtraction of the cpm bound in the presence of 50-100× excess of cold ligand. Binding data assays were analyzed us...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208977(US9233167, 6-O-mPEG3-Nalbuphine)
Affinity DataIC50: 398nMpH: 7.4 T: 2°CAssay Description:Test compound and/or vehicle was preincubated with the cell membranes and 3 uM GDP in modified HEPES buffer (pH 7.4) for 20 minutes, followed by addi...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208983(US9233167, a-6-mPEG2-O-Morphine)
Affinity DataKi:  404nM ΔG°:  -36.5kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208987(US9233167, a-6-mPEG6-O-Morphine)
Affinity DataEC50:  415nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208985(US9233167, a-6-mPEG4-O-Morphine)
Affinity DataKi:  439nM ΔG°:  -36.3kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetKappa-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM208982(US9233167, a-6-mPEG1-O-Morphine)
Affinity DataKi:  445nM ΔG°:  -36.3kJ/moleT: 2°CAssay Description:Briefly, serial dilutions of the test compounds were placed in a 96-well plate to which were added SPA beads, membrane and radioligand. The assay con...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

TargetMu-type opioid receptor(Human)
Nektar Therapeutics

US Patent
LigandPNGBDBM50370595(US9233167, Oxycodone | Oxycontin | OXYCODONE | US1...)
Affinity DataEC50:  478nMT: 2°CAssay Description:Briefly, suspensions of cells expressing either the mu, kappa or delta opioid receptors were prepared in buffer containing 0.5 mM isobutyl-methyl xan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/18/2017
Entry Details
US Patent

Displayed 1 to 50 (of 124 total ) | Next | Last >>
Jump to: